Twice-weekly teriparatide improves lumbar spine BMD independent of pre-treatment BMD and bone turnover marker levels.

Takada J, Yoshimura T, Uzawa T

Journal of bone and mineral metabolism3 Jan 2021Cited by 3 (Europe PMC)

PMID33389132DOI10.1007/s00774-020-01186-yPepBankPUB-33389132

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone5

In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Teriparatide (PTH 1-34).

01HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyEfficacy outcome
In TWICE trial patients, lumbar spine BMD increased significantly across all tertiles of baseline BMD and bone turnover markers.
In plain wordsIn trial patients, spine bone density increased from baseline across all initial bone density and bone turnover marker groups.
Peptide
Teriparatide (PTH 1-34)
Outcome
IncreaseLumbar spine BMD across baseline tertiles
Study
n: not reported in source
Comparator
baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
Across all tertile groups divided based on baseline LS-BMD and levels of bone turnover markers, the LS-BMD increased significantly.
2 context sentences(design, population, supporting numbers)
Summary · context
An analysis was performed using data from a double-blind, randomized, non-inferiority trial (TWICE study) conducted with patients who received 2/W-TPTD or a 56.5-μg teriparatide formulation for once-weekly use (1/W-TPTD) for 48 weeks.
Summary · context
The patients were divided into tertile groups based on baseline LS-BMD, urinary type I collagen cross-linked N-telopeptide (u-NTX), and serum type I procollagen-N-propeptide (P1NP) levels, respectively.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3338913201
02HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyActivity measurement
In TWICE trial patients, u-NTX decreased throughout treatment in the high- and middle-baseline u-NTX groups.
In plain wordsIn trial patients with high or middle initial u-NTX, u-NTX decreased from baseline throughout treatment.
Peptide
Teriparatide (PTH 1-34)
Outcome
Decreaseu-NTX in high and middle baseline groups
Study
n: not reported in source
Comparator
baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The u-NTX level decreased throughout the study period in the high- and middle-u-NTX-level groups.
2 context sentences(design, population, supporting numbers)
Summary · context
An analysis was performed using data from a double-blind, randomized, non-inferiority trial (TWICE study) conducted with patients who received 2/W-TPTD or a 56.5-μg teriparatide formulation for once-weekly use (1/W-TPTD) for 48 weeks.
Summary · context
The patients were divided into tertile groups based on baseline LS-BMD, urinary type I collagen cross-linked N-telopeptide (u-NTX), and serum type I procollagen-N-propeptide (P1NP) levels, respectively.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3338913202
03HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyActivity measurement
In TWICE trial patients with high baseline P1NP, P1NP increased after 4 weeks and subsequently decreased after 12 weeks and thereafter.
In plain wordsIn trial patients with high initial P1NP, P1NP rose after 4 weeks and later fell after 12 weeks.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedP1NP in high baseline group
Study
n: not reported in source
Comparator
baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
The P1NP level increased after 4 weeks, but subsequently decreased after 12 weeks and thereafter in the high-P1NP-level group;
2 context sentences(design, population, supporting numbers)
Summary · context
An analysis was performed using data from a double-blind, randomized, non-inferiority trial (TWICE study) conducted with patients who received 2/W-TPTD or a 56.5-μg teriparatide formulation for once-weekly use (1/W-TPTD) for 48 weeks.
Summary · context
The patients were divided into tertile groups based on baseline LS-BMD, urinary type I collagen cross-linked N-telopeptide (u-NTX), and serum type I procollagen-N-propeptide (P1NP) levels, respectively.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3338913203
04HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyActivity measurement
In TWICE trial patients with middle baseline P1NP, P1NP increased after 4 weeks and subsequently fluctuated near baseline.
In plain wordsIn trial patients with middle initial P1NP, P1NP rose after 4 weeks and then fluctuated near baseline.
Peptide
Teriparatide (PTH 1-34)
Outcome
MixedP1NP in middle baseline group
Study
n: not reported in source
Comparator
baseline
Outcome group
Bone and joint · Musculoskeletal
Source sentences
Summary
it increased after 4 weeks and subsequently fluctuated near the baseline level in the middle-P1NP-level group.
2 context sentences(design, population, supporting numbers)
Summary · context
An analysis was performed using data from a double-blind, randomized, non-inferiority trial (TWICE study) conducted with patients who received 2/W-TPTD or a 56.5-μg teriparatide formulation for once-weekly use (1/W-TPTD) for 48 weeks.
Summary · context
The patients were divided into tertile groups based on baseline LS-BMD, urinary type I collagen cross-linked N-telopeptide (u-NTX), and serum type I procollagen-N-propeptide (P1NP) levels, respectively.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3338913204
05HumanNot a test of Teriparatide (PTH 1-34) aloneObservational studyOther
In TWICE trial patients, the 4-week P1NP change threshold predicted lumbar spine BMD gains of at least 3% with 89.6% positive predictive value.
In plain wordsIn trial patients, early P1NP change predicted later spine bone density gains with a positive predictive value of 89.6%.
Peptide
Teriparatide (PTH 1-34)
Outcome
Not applicableP1NP change prediction of BMD response
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Measurements
P1NP change cutoff
12 µg/L
after 4 weeks of twice-weekly teriparatide
positive predictive value
89.6%
LS-BMD gain of 3% or more after 48 weeks
Source sentences
Summary
A cut-off value of 12.0 µg/L for change in P1NP after 4 weeks of 2/W-TPTD as a predictor for percentage change in LS-BMD of 3% or more after 48 weeks gave a positive predictive value of 89.6%.
2 context sentences(design, population, supporting numbers)
Summary · context
An analysis was performed using data from a double-blind, randomized, non-inferiority trial (TWICE study) conducted with patients who received 2/W-TPTD or a 56.5-μg teriparatide formulation for once-weekly use (1/W-TPTD) for 48 weeks.
Summary · context
The patients were divided into tertile groups based on baseline LS-BMD, urinary type I collagen cross-linked N-telopeptide (u-NTX), and serum type I procollagen-N-propeptide (P1NP) levels, respectively.
In this study, Teriparatide (PTH 1-34) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Teriparatide (PTH 1-34).
Report a problemFND-3338913205

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.